These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33297341)

  • 21. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial.
    Haidari G; Cope A; Miller A; Venables S; Yan C; Ridgers H; Reijonen K; Hannaman D; Spentzou A; Hayes P; Bouliotis G; Vogt A; Joseph S; Combadiere B; McCormack S; Shattock RJ
    Sci Rep; 2017 Oct; 7(1):13011. PubMed ID: 29026141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electroporation of a nanoparticle-associated DNA vaccine induces higher inflammation and immunity compared to its delivery with microneedle patches in pigs.
    Bernelin-Cottet C; Urien C; McCaffrey J; Collins D; Donadei A; McDaid D; Jakob V; Barnier-Quer C; Collin N; Bouguyon E; Bordet E; Barc C; Boulesteix O; Leplat JJ; Blanc F; Contreras V; Bertho N; Moore AC; Schwartz-Cornil I
    J Control Release; 2019 Aug; 308():14-28. PubMed ID: 31265882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8
    Li SS; Kochar NK; Elizaga M; Hay CM; Wilson GJ; Cohen KW; De Rosa SC; Xu R; Ota-Setlik A; Morris D; Finak G; Allen M; Tieu HV; Frank I; Sobieszczyk ME; Hannaman D; Gottardo R; Gilbert PB; Tomaras GD; Corey L; Clarke DK; Egan MA; Eldridge JH; McElrath MJ; Frahm N;
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28931520
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults.
    Chi RC; Rock MT; Neuzil KM
    Clin Infect Dis; 2010 May; 50(10):1331-8. PubMed ID: 20377407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli C; Groth N; Levin Y; Del Giudice G
    Hum Vaccin Immunother; 2014; 10(6):1701-10. PubMed ID: 24732325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
    Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of acceptability and usability of new delivery prototype device for intradermal vaccination in healthy subjects.
    Van Mulder TJ; Verwulgen S; Beyers KC; Scheelen L; Elseviers MM; Van Damme P; Vankerckhoven V
    Hum Vaccin Immunother; 2014; 10(12):3746-53. PubMed ID: 25531808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancing Immunogenicity of Influenza Vaccine in the Elderly through Intradermal Vaccination: A Literature Analysis.
    Quach HQ; Kennedy RB
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation.
    LeBlanc R; Vasquez Y; Hannaman D; Kumar N
    Vaccine; 2008 Jan; 26(2):185-92. PubMed ID: 18054817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
    Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
    PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
    Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
    Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.
    Ansaldi F; Valle L; de Florentiis D; Parodi V; Murdaca G; Bruzzone B; Durando P; Setti M; Icardi G
    Hum Vaccin Immunother; 2012 Aug; 8(8):1048-52. PubMed ID: 22832261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16).
    Launay O; Surenaud M; Desaint C; Ben Hamouda N; Pialoux G; Bonnet B; Poizot-Martin I; Gonzales G; Cuzin L; Bourgault-Villada I; Lévy Y; Choppin J; Durier C
    Vaccine; 2013 Sep; 31(40):4406-15. PubMed ID: 23850610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intramuscular vs intradermal route for hepatitis B booster vaccine in celiac children.
    Leonardi S; Praticò AD; Lionetti E; Spina M; Vitaliti G; La Rosa M
    World J Gastroenterol; 2012 Oct; 18(40):5729-33. PubMed ID: 23155313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial.
    Tawinprai K; Siripongboonsitti T; Porntharukchareon T; Wittayasak K; Thonwirak N; Soonklang K; Sornsamdang G; Auewarakul C; Mahanonda N
    Vaccine; 2022 Mar; 40(12):1761-1767. PubMed ID: 35210118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation.
    Dolter KE; Evans CF; Ellefsen B; Song J; Boente-Carrera M; Vittorino R; Rosenberg TJ; Hannaman D; Vasan S
    Vaccine; 2011 Jan; 29(4):795-803. PubMed ID: 21094270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.
    Cheeseman HM; Day S; McFarlane LR; Fleck S; Miller A; Cole T; Sousa-Santos N; Cope A; Cizmeci D; Tolazzi M; Hwekwete E; Hannaman D; Kratochvil S; McKay PF; Chung AW; Kent SJ; Cook A; Scarlatti G; Abraham S; Combadiere B; McCormack S; Lewis DJ; Shattock RJ
    Hum Gene Ther; 2018 Sep; 29(9):1011-1028. PubMed ID: 30027768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals.
    Morrow MP; Tebas P; Yan J; Ramirez L; Slager A; Kraynyak K; Diehl M; Shah D; Khan A; Lee J; Boyer J; Kim JJ; Sardesai NY; Weiner DB; Bagarazzi ML
    Mol Ther; 2015 Mar; 23(3):591-601. PubMed ID: 25531694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.